1-4 of 4
William T. Bellamy
Close
Sort by
Journal Articles

Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients with Poor Prognosis Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Francis J. Giles, MD, Heidi Steinfeldt, William T. Bellamy, MD, Paul Bycott, PhD, Yazdi Pithavala, PhD, Steven D. Reich, MD, Alan F. List, MD
Journal: Blood
Blood (2004) 104 (11): 1813.
https://doi.org/10.1182/blood.V104.11.1813.1813
Published: 2004
Journal Articles

Immunohistochemical Characterisation of Vascular Endothelial Growth Factor (VEGF) and its Receptors Flt-1 and KDR in Chronic Myeloid Leukaemia (CML) Patients Treated with Imatinib Mesylate.

Dragana Milojkovic, MD, Satyajit Sahu, MD, Jeffery Henderson, MD, Barbara H. Czepulkowski, John R. Salisbury, MD, William T. Bellamy, MD, Stephen Devereux, MD, Antonio Pagliuca, MD, Aloysius Y.L. Ho, MD, Ghulam J. Mufti, MD
Journal: Blood
Blood (2004) 104 (11): 1999.
https://doi.org/10.1182/blood.V104.11.1999.1999
Published: 2004
Journal Articles

Angiopoietin expression in multiple myeloma

William T. Bellamy
Journal: Blood
Blood (2003) 102 (2): 417–418.
https://doi.org/10.1182/blood-2003-05-1562
Published: 2003
Journal Articles

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes

William T. Bellamy, Lynne Richter, Davuud Sirjani, Concepcion Roxas, Betty Glinsmann-Gibson, Yvette Frutiger, Thomas M. Grogan, Alan F. List
Journal: Blood
Blood (2001) 97 (5): 1427–1434.
https://doi.org/10.1182/blood.V97.5.1427
Published: 2001